Clinical Study
Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs
Table 2
Demographic, clinical, and CEUS characteristics of the patients before and at 12 months of anti-TN therapy.
| Patient number | Gender | Age | Duration Pso (yrs) | Duration PsA (yrs) | Therapy | Month 0 | Month 12 | TJC | SJC | Dactylitis | Enthesitis | CEUS | PASI | TJC | SJC | Dactylitis | Enthesitis | CEUS | PASI |
| 1 | F | 37 | 22 | 2 | Adalimumab | 10 | 0 | No | No | 2 | 0.2 | 10 | 0 | No | No | 1 | 1.0 | 2 | M | 45 | 24 | 15 | Etanercept | 18 | 1 | No | No | 3 | 3.7 | 0 | 0 | No | No | 0 | 0.0 | 3 | F | 27 | 25 | 3 | Etanercept | 19 | 0 | No | Yes | 3 | 0.0 | 0 | 0 | No | No | 0 | 0.0 | 4 | F | 48 | 6 | <1 | Adalimumab | 48 | 7 | Yes | No | 2 | 0.9 | 51 | 0 | No | Yes | 2 | 0.0 | 5 | M | 55 | 3 | 3 | Adalimumab | 4 | 2 | Yes | No | 3 | 2.8 | 1 | 0 | No | No | 1 | 0.0 | 6 | F | 47 | 27 | 1 | Adalimumab | 12 | 3 | No | Yes | 3 | 10 | 4 | 0 | No | Yes | 1 | 2.4 | 7 | F | 63 | 21 | 21 | Adalimumab | 11 | 2 | No | Yes | 3 | 2.0 | 0 | 0 | No | No | 1 | 1.6 | 8 | F | 64 | 24 | 3 | Etanercept | 3 | 0 | No | Yes | 3 | 3.1 | 0 | 0 | No | No | 2 | 0.0 | 9 | F | 54 | 40 | 7 | Etanercept | 3 | 2 | No | No | 2 | 2.9 | 4 | 1 | No | No | 0 | 1.9 | 10 | F | 66 | 32 | <1 | Etanercept | 10 | 6 | No | No | 1 | 2.7 | 8 | 0 | No | No | 0 | 0.8 | 11 | M | 48 | 4 | 1.5 | Etanercept | 17 | 2 | Yes | Yes | 3 | 1.2 | 1 | 1 | No | No | 0 | 0.0 | 12 | M | 58 | 24 | 14 | Etanercept | 1 | 1 | No | No | 0 | 2.7 | 0 | 0 | No | No | 0 | 0.0 | 13 | M | 41 | 23 | 1 | Etanercept | 2 | 1 | No | No | 2 | 2.6 | 0 | 0 | No | No | 0 | 0.0 | 14 | M | 54 | 36 | 16 | Adalimumab | 8 | 0 | No | No | 1 | 9.6 | 10 | 0 | No | No | 1 | 6.6 | 15 | M | 43 | 28 | 22 | Adalimumab | 17 | 6 | No | Yes | 3 | 20.4 | 1 | 0 | No | Yes | 0 | 0.0 | 16 | F | 59 | 46 | 20 | Etanercept | 2 | 2 | Yes | No | 0 | 3.2 | 0 | 0 | No | No | 0 | 1.8 | 17 | M | 36 | 2 | 1.5 | Adalimumab | 11 | 4 | No | No | 2 | 1.2 | 0 | 0 | No | No | 0 | 0.0 | 18 | M | 44 | 31 | 31 | Etanercept | 4 | 4 | No | No | 2 | 2.8 | 0 | 0 | No | No | 1 | 2.0 | 19 | F | 54 | 4 | 2 | Adalimumab | 15 | 3 | No | Yes | 3 | 2.4 | 15 | 0 | No | Yes | 1 | 0.0 | 20 | F | 51 | 15 | <1 | Adalimumab | 8 | 2 | No | Yes | 3 | 0.8 | 2 | 0 | No | No | 1 | 0.0 | 21 | M | 62 | 10 | <1 | Etanercept | 3 | 0 | No | No | 2 | 2.6 | 1 | 1 | No | No | 0 | 2.1 | 22 | M | 65 | 5 | 3 | Etanercept | 3 | 2 | Yes | No | 2 | 5.2 | 1 | 1 | No | No | 1 | 2.1 | 23 | M | 69 | 19 | <1 | Etanercept | 6 | 0 | No | No | 0 | 5.9 | 0 | 0 | No | No | 0 | 5.0 | 24 | F | 29 | 8 | 3 | Etanercept | 10 | 1 | No | No | 1 | 0.2 | 0 | 0 | No | Yes | 1 | 0.0 | 25 | M | 45 | 24 | 2 | Etanercept | 9 | 2 | Yes | No | 3 | 4.5 | 0 | 0 | No | No | 0 | 3.6 |
|
|
TJC: tender joint count; SJC: swollen joint count; CEUS: contrast-enhanced ultrasound; PASI: Psoriasis Area Severity Index.
|